Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series

Abstract

Tic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/ severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.